Kapruvia® receives positive CHMP opinion for the treatm

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patientsAD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LRCommittee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia®(difelikefalin) as first therapy in Europe for the treatment of chr...

Related Keywords

Norway , Iceland , United States , Liechtenstein , Switzerland , Swiss , Christopher Posner , Vifor Pharma , Klaus Henning Jensen , Instagram , Linkedin , Twitter , International Journal Of Nephrology , Nasdaq , Cara Therapeutics Inc , Vifor Pharma Group , European Union , National Registry Study , Committee For Medicinal Products Human Use , Swiss Stock Exchange , European Commission , Swiss Exchange , Exchange Commission , European Medicines Agency , Fresenius Medical Care , Medicinal Products , Human Use , Fresenius Medical Care Renal Pharma , Cara Therapeutics , Chief Medical Officer , Chief Executive Officer , Cara Therapeutic , Pharma Group , Sanifit Therapeutics , Vifor Fresenius Medical Care Renal Pharma , Chronic Kidney Disease Associated Pruritus , Registry Study , Private Securities Litigation Reform Act , Quarterly Report , Dialysis Outcomes , Practice Patterns , Nephrol Dial , Patient Reported Outcomes , Uremic Pruritus ,